How to Get GLP-1 Medication in 2026: Every Option Compared — Medicare, TrumpRx, Insurance, and Cash-Pay From $86/Month

The GLP-1 Access Landscape Changed Completely in 2026

If you researched GLP-1 medication costs a year ago, some of what you learned is already out of date. Three developments have reshaped how Americans access semaglutide and tirzepatide in 2026:

Federal pricing agreements brought branded prices down significantly. In November 2025, the Trump administration announced most-favored-nation pricing agreements with Novo Nordisk and Eli Lilly. Under those agreements, Medicare and Medicaid pay $245 per month for injectable Ozempic, Wegovy, Mounjaro, and Zepbound — down from list prices exceeding $1,000 per month. General cash-pay consumers buying through the TrumpRx platform or the manufacturers' own self-pay programs see somewhat higher prices today, ranging from roughly $149/month for the Wegovy pill up to $449/month for higher-dose Zepbound, with the manufacturers' agreement committing to bring consumer pricing down further over the next two years.

Medicare now covers GLP-1s for eligible beneficiaries. The CMS Medicare GLP-1 Bridge, a demonstration program running from July 1, 2026 through December 31, 2027, offers eligible Medicare Part D beneficiaries access to select GLP-1 medications at $50 monthly copays — the first meaningful Medicare pathway for weight-management GLP-1s since the Medicare Modernization Act of 2003 barred Part D from covering weight-loss drugs.

Oral GLP-1s arrived. The Wegovy pill became available in January 2026, and orforglipron (brand name Foundayo), Eli Lilly's oral GLP-1, was FDA-approved in April 2026 — expanding options beyond injections for the first time.

Despite all of this, fewer than one in ten eligible patients currently takes any GLP-1 medication. The biggest barrier is no longer supply — it's confusion. Most patients don't know which access pathway applies to them or what each one actually costs once you look past the headline number.

This guide compares every option, with real monthly costs and eligibility requirements for each.

Option 1: Medicare Bridge Program — $50/Month Copay (Eligible Beneficiaries)

Who it's for: Medicare Part D beneficiaries who meet the clinical criteria under the CMS demonstration.

What it costs: A $50 monthly copay for covered GLP-1 medications.

What to know: The Medicare GLP-1 Bridge runs from July 1, 2026 through December 31, 2027. It's the first meaningful Medicare pathway for weight-management GLP-1s — Medicare was previously barred from covering weight-loss drugs under the 2003 Medicare Modernization Act. Eligibility is limited to specific clinical criteria, rollout timing varies by Part D plan, and the $50 copay does not count toward a beneficiary's true out-of-pocket (TrOOP) costs. Patients should verify their specific eligibility directly with Medicare or their plan administrator.

The catch: Most Americans searching for GLP-1 access are not Medicare beneficiaries. If you're under 65 and not on Medicare due to disability, this pathway doesn't apply to you.

Option 2: TrumpRx and Manufacturer Self-Pay — From $149/Month (Branded, Cash-Pay)

Who it's for: Any patient willing to pay cash for FDA-approved branded medication, with or without insurance.

What it costs: Pricing varies meaningfully by drug, dose, and formulation. As of mid-2026: the Wegovy pill runs about $149–$199/month, standard-dose Wegovy injections run about $349/month ($399/month for the highest 7.2 mg dose), and Zepbound runs from about $299/month at the lowest dose up to $449/month at higher doses. These prices are available directly through TrumpRx.gov and the manufacturers' own self-pay programs, NovoCare and LillyDirect, which function as the same underlying pricing tier.

What to know: This is a genuine improvement over prior list prices, which regularly exceeded $1,000/month. It's worth being precise about one figure that gets circulated a lot: the widely reported $245/month price is what Medicare and Medicaid pay under the federal pricing agreement — not the price a general cash-pay consumer sees today. The manufacturers have committed to bringing consumer self-pay prices down toward that level over roughly the next two years, but as of this writing, actual self-pay prices are higher than $245/month for most doses.

The catch: Even at the lower end, branded self-pay costs multiple times what a compounded alternative costs, and for a medication most patients take for a year or longer, that difference compounds. At $349/month, standard-dose Wegovy runs about $4,188/year on an ongoing basis — versus $1,740/year for Ozari's ongoing quarterly semaglutide plan ($145/month after the introductory period).

Option 3: Commercial Insurance — Copay Varies (If You Can Get Coverage)

Who it's for: Patients with commercial insurance plans that cover weight-management GLP-1s.

What it costs: Anywhere from $0 to full retail price, depending on the plan, deductible, and prior authorization outcome.

What to know: Coverage for weight-management GLP-1s remains inconsistent across commercial plans. Many plans still exclude anti-obesity medications entirely. Plans that do cover them typically require prior authorization — documentation of BMI, comorbidities, and often a history of prior weight-loss attempts — and denials remain common for patients without a type 2 diabetes diagnosis.

The catch: The prior authorization process can take weeks to months, and a denial after that wait leaves patients back where they started. For patients whose plans exclude weight-management medications outright, this pathway is a dead end regardless of clinical need. Ozari Health's guide to getting a GLP-1 prescription without insurance covers this in more depth.

Option 4: Cash-Pay Compounded Telehealth — From $86/Month

Who it's for: Cash-pay patients who don't qualify for Medicare, lack commercial coverage, or want the lowest-cost legitimate option.

What it costs: Compounded semaglutide from $86/month and compounded tirzepatide from $125/month at Ozari Health for eligible starter-plan patients — all-in, with no membership fees and no long-term contracts.

What to know: Compounded GLP-1 medications are prepared by US-licensed compounding pharmacies under patient-specific prescriptions issued by a licensed provider. They contain the same active pharmaceutical ingredient as branded products when properly sourced — semaglutide base or tirzepatide base — but they are not FDA-approved and are not generic versions of Ozempic, Wegovy, Mounjaro, or Zepbound.

For this pathway, provider legitimacy matters more than for any other option on this list, because there's no manufacturer or insurer standing between the patient and the product. A legitimate compounded GLP-1 provider requires licensed provider review before any prescription, names its pharmacy partners, publishes all-in pricing, and holds independent certification such as LegitScript — verifiable directly at legitscript.com. Ozari Health's pharmacy standards page documents its own compounding partners and credentialing in detail.

The catch: Compounded medications lack FDA approval, and the clinical trial data most often cited — the STEP 1 trial's 14.9% mean weight loss for semaglutide (NEJM, 2021) and the SURMOUNT-1 trial's 20.9% at the highest tirzepatide dose (NEJM, 2022) — studied the FDA-approved formulations, not compounded versions. Patients should understand that distinction clearly before choosing this pathway.

Side-by-Side: Every GLP-1 Access Option in 2026

How to Choose the Right Pathway

• If you're on Medicare: Check your eligibility for the bridge program first — a $50 copay beats every other option if you qualify.
• If you have commercial insurance: Call your plan and ask specifically whether weight-management GLP-1s are covered and what prior authorization requires. If it's covered with a reasonable copay, pursue it — but set a time limit. If prior auth drags past 30 days or gets denied, move to a cash-pay option.
• If you're cash-pay and want FDA-approved branded medication: TrumpRx and manufacturer self-pay pricing — roughly $149 to $449/month depending on the drug and dose — is now the branded benchmark.
• If you're cash-pay and want the lowest legitimate cost: Compounded telehealth from $86/month at Ozari Health is the lowest-cost pathway — provided you choose a certified provider with licensed clinical review and named pharmacy partners.
• If you're a Spanish speaker: Ozari Health offers its full platform, intake process, and clinician-reviewed resources in Spanish at ozarihealth.com/es — one of the few GLP-1 telehealth platforms with complete Spanish-language support.

What Every Pathway Has in Common

No matter which option you choose, three things should always be true:

• A licensed provider evaluates you before prescribing. GLP-1 medications have real contraindications — including a personal or family history of medullary thyroid carcinoma or MEN 2, active pancreatitis, and pregnancy. Any pathway that skips clinical evaluation is not legitimate, regardless of price.
• You know the true monthly cost before committing. Advertised prices frequently exclude membership fees, dose-escalation increases, or supply costs. Ask for the all-in monthly cost at a stable maintenance dose — not just the starting price.
• You understand what you're getting. FDA-approved branded, or compounded? Injectable or oral? These are different products with different regulatory status, and any provider unwilling to explain the difference clearly should be avoided.

Frequently Asked Questions

What is the cheapest way to get GLP-1 medication in 2026?

For eligible Medicare beneficiaries, the bridge program's $50/month copay is cheapest. For everyone else, cash-pay compounded telehealth is generally the lowest-cost legitimate pathway — compounded semaglutide starts at $86/month at Ozari Health, compared to roughly $149–$449/month for branded medication through TrumpRx or manufacturer self-pay programs.

How does the Medicare GLP-1 bridge program work?

The CMS demonstration running from July 1, 2026 through December 31, 2027 allows eligible Medicare Part D beneficiaries to access select GLP-1 medications at $50 monthly copays. Eligibility criteria and rollout timing vary by plan — verify directly with Medicare or your plan administrator before assuming you qualify.

What is TrumpRx pricing for Ozempic and Wegovy?

Under the federal pricing agreements announced in November 2025, Medicare and Medicaid pay $245 per month for injectable branded GLP-1s. General cash-pay consumers buying directly through TrumpRx or the manufacturers' self-pay programs currently see higher prices that vary by drug and dose — for example, around $349/month for standard-dose Wegovy and $299–$449/month for Zepbound depending on dose. Consumer pricing is expected to decline further over the next two years under the same agreement.

Is compounded semaglutide as good as Wegovy?

Compounded semaglutide contains the same active ingredient as Wegovy when properly sourced, but it is not FDA-approved and has not itself been studied in clinical trials. The published weight-loss data — 14.9% mean reduction in the STEP 1 trial — applies to FDA-approved semaglutide. Patients should weigh the cost difference against this regulatory and evidentiary difference before choosing.

How much does Ozari Health cost compared to other options?

Ozari's compounded semaglutide starts at $86/month and tirzepatide at $125/month for eligible patients — compared to roughly $149–$449/month for branded medication through TrumpRx or manufacturer self-pay, or $50/month copays for the limited group of patients who qualify for Medicare's bridge program.

Can I get GLP-1 medication without insurance?

Yes. TrumpRx and manufacturer self-pay pricing (roughly $149–$449/month depending on the drug and dose) and cash-pay compounded telehealth (from $86/month) both work without insurance.

Are oral GLP-1 pills available now?

Yes. The Wegovy pill became available in January 2026, and orforglipron (Foundayo) was FDA-approved in April 2026. Oral options currently show somewhat lower average weight loss than injectables in published trial data — around 12% at orforglipron's top dose — but eliminate injections entirely.

How do I verify a GLP-1 telehealth provider is legitimate?

Check for LegitScript certification at legitscript.com, confirm licensed provider review happens before any prescription, look for named pharmacy partners, published all-in pricing, and accurate medication language — a legitimate provider will never describe a compounded medication as "generic Ozempic" or "generic Wegovy."

---

---

This article is for informational purposes only and does not constitute medical advice. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness, or quality. Program details, pricing, and eligibility criteria for federal and Medicare programs described above may change — verify current details with official sources before making a decision. Clinical trial results for FDA-approved products should not be extrapolated as guaranteed outcomes for compounded medications. Individual results vary. Always consult a licensed healthcare provider before starting any prescription medication. Ozari Health is a telehealth platform that connects patients with licensed, independent healthcare providers.